KPC(SH:600422)2018-04-12 16:00Financial Performance - Operating revenue rose by 35.16% to CNY 1,642,369,522.37 year-on-year[5] - Net profit attributable to shareholders decreased by 12.91% to CNY 82,253,681.31 compared to the same period last year[5] - Basic and diluted earnings per share fell by 11.95% to CNY 0.1054[5] - Total operating revenue for Q1 2018 reached ¥1,642,369,522.37, an increase of 35.0% compared to ¥1,215,145,409.67 in the same period last year[20] - Net profit attributable to shareholders of the parent company was ¥82,253,681.31, a decrease of 13.0% from ¥94,441,874.34 in the previous year[21] - The company reported a basic earnings per share of ¥0.1054, down from ¥0.1197 in the previous year[21] - The total profit for Q1 2018 was CNY 58.24 million, a slight decrease from CNY 75.35 million in Q1 2017[23] Assets and Liabilities - Total assets increased by 6.26% to CNY 6,735,140,345.92 compared to the end of the previous year[5] - Total liabilities increased to ¥1,505,048,003.88, up 30.3% from ¥1,155,096,201.18 at the start of the year[19] - Current assets totaled ¥2,217,002,896.08, an increase of 9.3% from ¥2,029,245,200.39 at the beginning of the year[18] - Cash and cash equivalents rose significantly to ¥542,853,190.75, compared to ¥241,107,034.45 at the start of the year, marking a growth of 125.5%[18] - The total equity attributable to shareholders of the parent company was ¥3,296,542,418.80, an increase from ¥3,246,769,981.73 at the beginning of the year[20] Cash Flow - Net cash flow from operating activities worsened by 118.16%, reaching -CNY 158,289,792.91[5] - The cash flow from operating activities showed a net outflow of CNY 158.29 million, compared to a net outflow of CNY 72.56 million in the previous year[24] - The total cash and cash equivalents at the end of Q1 2018 were CNY 797.07 million, down from CNY 985.01 million at the end of Q1 2017[25] - Cash flow from financing activities showed a significant increase of 3,795.53% to ¥331.23 million, indicating enhanced financing efforts[10] - Cash flow from financing activities resulted in a net inflow of 280,288,794.32 CNY, with total cash inflow of 293,502,681.00 CNY[27] Expenses - Operating costs rose by 25.63% to ¥837.73 million, attributed to business scale expansion and changes in marketing strategies[10] - Sales expenses increased by 69.65% to ¥603.18 million, driven by business expansion and increased market investment[10] - Management expenses grew by 29.70% to ¥92.32 million, influenced by an expanded consolidation scope and increased R&D investment[10] - The company incurred sales expenses of CNY 287.19 million, which is a 54.4% increase from CNY 186.06 million in the previous year[23] - The financial expenses for Q1 2018 were CNY 5.58 million, up from CNY 2.90 million in Q1 2017[23] Shareholder Information - The total number of shareholders reached 58,705 at the end of the reporting period[8] - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 29.88% of shares, with 106,428,266 shares pledged[8] - The company plans to repurchase shares using ¥200 million to ¥500 million of its own funds to enhance shareholder value[11] Other Information - Non-recurring gains and losses totaled CNY 19,122,514.97, primarily from government subsidies and asset disposals[6] - The company has not disclosed any significant new product developments or market expansion strategies in this report[9] - Accounts receivable increased by 56.48% to ¥234.37 million due to an increase in customer settlements using notes[10] - Other comprehensive income rose by 92.24% to ¥4.69 million, primarily due to foreign currency translation differences[10] - The company received 820,000,000.00 CNY from investment recoveries, a decrease from 1,163,134,600.00 CNY in the same quarter last year[27] - The company paid 818,000,000.00 CNY for investments, an increase from 665,032,922.00 CNY in Q1 2017[27]